MDxHealth Provides First Quarter 2018

NEXT STORY
Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May
PREV STORY
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Zika virus discovery marks success of Purdue life sciences investment

West Lafayette, Ind., March 31, 2016 (GLOBE NEWSWIRE) -- Note to Journalists: A gallery of ...

author_avatar
NASDAQ Market News

Targovax to present at forthcoming conferences

OSLO, Norway, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Targovax (OSE: TRVX, or "the Company"), ...

author_avatar
NASDAQ Market News

ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities

Company to host conference call today at 4:30 p.m. ETPivotal, randomized control trial in ...

author_avatar
NASDAQ Market News